The company makes blood tests that help cancer doctors select the right treatment for their patients. The San Diego-based company raised $19 million after offering 1.9 million shares at $10 per share. It plans to use the cash it raised to hire sales and marketing employees, fund research and development and buy equipment. Its shares are listed on the Nasdaq under the ticker symbol "BIOC" and fell 60 cents, or 6 percent, to $9.40.
Description
Biocept, Inc.(Biocept) is a cancer diagnostics company. The Company develops and commercializes circulating tumor cell (CTC), and circulating tumor Deoxyribonucleic acid (DNA), (ctDNA), tests utilizing a standard blood sample. These tests (including its OncoCEE-BRTM breast cancer CTC test, which is already on the market) are designed to provide information to oncologists to enable them to select appropriate treatment. Cell Enrichment and Extraction (CEE) is an internally invented and developed, microfluidics-based CTC capture and analysis platform. Circulating tumor cells are cancer cells that have detached from the tumor matrix and invaded the patient’s blood or other bodily fluids. OncoCEE CTC tests for cancer types other than breast cancer, with a focus on population solid tumor types, or cancers for which there are approved therapies that rely on biomarker tests.
Address
Suite 150 5810 Nancy Ridge Drive
SAN DIEGO, CA 92121-2840
United States
SAN DIEGO, CA 92121-2840
United States
Website
http://www.biocept.comKey stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | -8960.50% | -11217.43% |
| Operating margin | -7438.85% | -9610.27% |
| EBITD margin | - | -9275.39% |
| Return on average assets | -1105.93% | -694.75% |
| Return on average equity | - | - |
| Employees | 27 |
No comments:
Post a Comment